Adverse effects on women: abdominal cramps · women in the postpartum period
Vitamin A supplementation (200,000 to 400,000 IU) showed no clear difference in maternal adverse effects after administration: abdominal pain compared with placebo or no treatment (low certainty).
1 finding from 1 review
Maternal breast milk retinol concentration · women in the postpartum period
1 finding from 1 review
Change in Infant Mortality Rate per 1000 live births1 · women in the postpartum period
Vitamin A supplementation (200,000 to 400,000 IU) showed no clear difference in infant mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
Infant morbidity (gastroenteritis) · women in the postpartum period
It is very uncertain whether vitamin A supplementation (200,000 to 400,000 IU) changes infant morbidity (gastroenteritis) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Infant adverse effects: bulging fontanelle · women in the postpartum period
Vitamin A supplementation (200,000 to 400,000 IU) showed no clear difference in infant adverse effects: bulging fontanelle compared with placebo or no treatment (low certainty).
1 finding from 1 review
Average mouth pain during RAS episodes · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Daily multivitamin showed no clear difference in average mouth pain during RAS episodes compared with placebo; GRADE not reported.
1 finding from 1 review
MD -0.05 [-0.71, 0.61]
1 study
GRADE not reported
Average number of new lesions per week · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Daily multivitamin showed no clear difference in mean number of new lesions compared with placebo; GRADE not reported.
1 finding from 1 review
MD -0.41 [-1.85, 1.03]
1 study
GRADE not reported
Duration of episodes · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Daily multivitamin showed no clear difference in duration of episodes compared with placebo; GRADE not reported.
1 finding from 1 review
MD -0.33 [-2.06, 1.40]
1 study
GRADE not reported
Serum/plasma retinol (μmol/L) · general population over 2 years of age
1 finding from 1 review
All‐cause mortality · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause morbidity · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause morbidity · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serum/plasma retinol (μmol/L) · general population over 2 years of age
1 finding from 1 review
Haemoglobin (g/dL) · general population of all age groups (including pregnant women) from any country, over two years of age
1 finding from 1 review
Serum/plasma retinol (μmol/L) · general population of all age groups (including pregnant women) from any country, over two years of age
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic VTE compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
It is very uncertain whether vitamin K antagonists changes symptomatic PE compared with placebo or no thromboprophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic DVT compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review